Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G.
Takahashi K, et al. Among authors: kantarjian h.
Oncotarget. 2016 Mar 22;7(12):14172-87. doi: 10.18632/oncotarget.7290.
Oncotarget. 2016.
PMID: 26871476
Free PMC article.